Generics

Alembic unveils generic Levitra

Alembic’s generic Levitra comes in dosage strengths of 10 mg and 20 mg in 30-count bottles.
FDA clears interchangeable insulin biosimilar Semglee

Semglee is both biosimilar to and interchangeable with Lantus, and is the first interchangeable biosimilar approved by the Food and Drug Administration.

Lannett inks distribution agreement for generic Spiriva Handihaler

Spiriva Handihaler had a market value of $1.5 billion for the 12 months ended May 2021, although actual generic market values are expected to be lower.
AAM taps Joanne Duncan as COO

Duncan will be responsible for leading and managing implementation of a more comprehensive member recruitment strategy at AAM.
Rolling with the punches: Generics firms innovate, expand scope to stay competitive

As they continue to navigate pandemic headwinds, generics firms look to broaden their portfolios and vertically integrate to keep competitive.
Beximco receives FDA nod for Baclofen

Baclofen had a market value of more than $110 million in 2020, according to IQVIA.
Roundup: Recent generic launches

Taking a look at some of the innovative new generics making their debut:
CDC guidance: Insurers must cover HIV prevention treatment costs

Insurers, which were required to stop charging out-of-pocket fees for PrEP as of Jan. 1, have 60 days to comply with the latest rules.
FDA tentatively OKs Zydus Cadila’s generic Imbruvica

Zydus Cadila's generic Imbruvica tablets provide a treatment for certain types of cancer.
Nexus debuts potassium chloride in water for injection

Potassium chloride injection is indicated in the treatment of potassium deficiency states when oral replacement is not feasible.
Intas, Meiji and Dong-A ST to commercialize Stelara biosimilar

Biosimilar ustekinumab will provide a treatment of autoimmune and inflammatory diseases such as plaque psoriasis, Crohn's disease and ulcerative colitis.
Aurobindo’s generic Adalat CC gets FDA OK

The market size of the product was $95 million for the 12-month period ended May 2021, according to IQVIA data.
FDA clears Amneal’s generic TobraDex

IQVIA data for the year ended May 2021 showed annual U.S. sales of TobraDex and its generics was $118 million.
Slayback names Pete Meyers CFO

Meyers most recently served as CFO of Eagle Pharmaceuticals.

News and information on generic drugs sold in retail pharmacies, as well as their suppliers.